Celcuity Stock Skyrockets 40% to Record High on ‘Practice-Changing’ Cancer Trial Results
Stock Soars on Positive Trial News Celcuity’s stock price skyrocketed on October 20, 2025 after the Minneapolis-based biotech reported game-changing clinical trial results. Shares jumped from around $52 to as high as $78–$81 intraday marketbeat.com, an approximately 40–50% single-day leap, before settling near a record high close. This surge marked a new 52-week high of $81.56 marketbeat.com and lifted Celcuity’s market capitalization above $2.2 billion investing.com. The stunning rally came on unusually heavy trading volume as investors rushed to buy shares, propelled by news from a major cancer conference. The immediate catalyst was Celcuity’s Phase 3 VIKTORIA-1 trial data presented over